Carmenta Bioscience Status
The company was acquired by Progenity for an undisclosed amount on April 29, 2015.
Developer of serum based diagnostic test for preeclampsia. The company focuses on maternal and fetal health by applying a systems biology approach to the diagnosis and prediction of preeclampsia.
Year Founded
2012
Employees
4
General Information
-
Website
-
Business Status
Startup
-
Ownership Status
Acquired/Merged (Operating Subsidiary)
-
Financing Status
Formerly Angel backed
Carmenta Bioscience News and Updates
Future-proofing ecosystem restoration through enhancing adaptive ...
Nature.com | April 7, 2023
Complex agricultural landscapes host more biodiversity than simple ...
pnas.org | September 12, 2022
Projections of future forest degradation and CO2 emissions for the ...
Science | June 15, 2022
Changes in land use enhance the sensitivity of tropical ecosystems ...
Nature.com | January 19, 2022
Assessing costs of Indonesian fires and the benefits of restoring ...
Nature.com | December 2, 2021
Progenity Acquires Carmenta Bioscience for Proprietary ...
Business Wire | April 29, 2015
Carmenta Bioscience's Verticals
Carmenta Bioscience Primary Industry Sector / Group / Code
Carmenta Bioscience's Trends
Headquarters
-
HQ Address Line 14240 Wilkie Way
-
HQ CityPalo Alto
-
HQ State/ProvinceCalifornia
-
HQ Post Code94306
-
HQ CountryUnited States
Carmenta Bioscience's Keywords
mood_badFeed is empty.
Add a review